Telix Pharmaceuticals Ltd
TLX10.280USD
-0.110-1.06%
Close 11/04, 16:00（ET）Quotes delayed by 15 min
0.00Market Cap
--P/E TTM
More Details of Telix Pharmaceuticals Ltd Company
Telix Pharmaceuticals Limited is an Australia-based biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals and associated medical devices. It develops a portfolio of clinical and commercial stage products that addresses significant unmet medical needs in oncology and rare diseases. It operates a pipeline of theranostic radiopharmaceutical product candidates with a focus on urologic oncology (prostate and kidney), neuro-oncology (glioma), musculoskeletal oncology (sarcoma) and bone marrow conditioning. Its segments include commercial, product development, medical technologies, and manufacturing services. Its lead imaging product is gallium-68 (68Ga) gozetotide injection (also known as 68Ga PSMA-11 and marketed under the brand name Illuccix). Its other pipelines include TLX591, TLX592, TLX250, TLX101, TLX300, TLX66, TLX66-CDx, and TLX090, among others.
Telix Pharmaceuticals Ltd Info
Ticker SymbolTLX
Company nameTelix Pharmaceuticals Ltd
IPO dateNov 15, 2017
CEOMr. Kevin Richardson
Number of employees- -
Security typeOrdinary Share
Fiscal year-end- -
Address55 Flemington Road
CityMELBOURNE
Stock exchangeXetra
CountryAustralia
Postal code3051
Phone61390933855
Websitehttps://telixpharma.com/
Ticker SymbolTLX
IPO dateNov 15, 2017
CEOMr. Kevin Richardson
Company Executives of Telix Pharmaceuticals Ltd
Name
Name/Position
Position
Shareholding
Change
Ms. Marie McDonald
Ms. Marie McDonald
Non-Executive Director
Non-Executive Director
--
--
Dr. Paul Schaffer
Dr. Paul Schaffer
Chief Technology Officer
Chief Technology Officer
--
--
Mr. Richard Valeix
Mr. Richard Valeix
Group Chief Commercial Officer
Group Chief Commercial Officer
--
--
Mr. James Stonecypher
Mr. James Stonecypher
Group Chief Development Officer
Group Chief Development Officer
--
--
Dr. Mark Nelson, Ph.D.
Dr. Mark Nelson, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Ms. Tiffany P. Olson
Ms. Tiffany P. Olson
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
--
--
Dr. Christian P. Behrenbruch, J.D., Ph.D.
Dr. Christian P. Behrenbruch, J.D., Ph.D.
Group Chief Executive Officer, Managing Director, Executive Director
Group Chief Executive Officer, Managing Director, Executive Director
--
--
Mr. Darren Smith, CPA
Mr. Darren Smith, CPA
Group Chief Financial Officer
Group Chief Financial Officer
--
--
Ms. Genevieve Ryan
Ms. Genevieve Ryan
Company Secretary
Company Secretary
--
--
Dr. David Cade
Dr. David Cade
Group Chief Medical Officer
Group Chief Medical Officer
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Ms. Marie McDonald
Ms. Marie McDonald
Non-Executive Director
Non-Executive Director
--
--
Dr. Paul Schaffer
Dr. Paul Schaffer
Chief Technology Officer
Chief Technology Officer
--
--
Mr. Richard Valeix
Mr. Richard Valeix
Group Chief Commercial Officer
Group Chief Commercial Officer
--
--
Mr. James Stonecypher
Mr. James Stonecypher
Group Chief Development Officer
Group Chief Development Officer
--
--
Dr. Mark Nelson, Ph.D.
Dr. Mark Nelson, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Ms. Tiffany P. Olson
Ms. Tiffany P. Olson
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
--
--
Revenue Breakdown
No Data
No Data
By Business
By Region
No Data
Shareholding Stats
Updated: Fri, Oct 17
Updated: Fri, Oct 17
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Pier Capital, LLC
0.06%
Russell Investments Trust Company
0.02%
Fidelity Management & Research Company LLC
0.01%
Citadel Advisors LLC
0.01%
Jane Street Capital, L.L.C.
0.01%
Other
99.89%
Shareholders
Shareholders
Proportion
Pier Capital, LLC
0.06%
Russell Investments Trust Company
0.02%
Fidelity Management & Research Company LLC
0.01%
Citadel Advisors LLC
0.01%
Jane Street Capital, L.L.C.
0.01%
Other
99.89%
Shareholder Types
Shareholders
Proportion
Investment Advisor
0.11%
Research Firm
0.01%
Hedge Fund
0.01%
Other
99.87%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
24
453.44K
0.13%
+376.86K
2025Q2
11
269.45K
0.08%
+265.72K
2025Q1
6
20.71K
0.01%
+16.98K
2024Q4
1
3.73K
0.00%
+3.73K
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Pier Capital, LLC
188.99K
0.06%
+188.99K
--
Jun 30, 2025
Russell Investments Trust Company
60.30K
0.02%
+60.30K
--
Jun 30, 2025
Fidelity Management & Research Company LLC
42.09K
0.01%
+42.09K
--
Jun 30, 2025
Citadel Advisors LLC
41.33K
0.01%
+41.33K
--
Jun 30, 2025
Jane Street Capital, L.L.C.
35.10K
0.01%
+35.10K
--
Jun 30, 2025
Private Advisor Group LLC
25.17K
0.01%
+15.03K
+148.20%
Jun 30, 2025
Vanguard Personalized Indexing Management, LLC
18.48K
0.01%
+18.48K
--
Jun 30, 2025
William Blair & Company, L.L.C. (Research)
13.50K
0%
+13.50K
--
Jun 30, 2025
IHT Wealth Management, LLC
13.24K
0%
+13.24K
--
Jun 30, 2025
UBS Financial Services, Inc.
6.12K
0%
+2.47K
+67.65%
Jun 30, 2025
View more
Related ETFs
Name
Proportion
No Data
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
